Hikma reiterates FY guidance amid 'strong momentum'
(Sharecast News) - Drugmaker Hikma Pharmaceuticals reiterated full-year guidance on Thursday, citing "strong momentum" in its injectables and branded units, but also cautioned that had begun to see the effects of the global inflationary environment on costs.
Read more